Regnum
$0
5
+$0+0% Thursday 20:00
Statistics
Day High
0
Day Low
0
52W High
0.5
52W Low
0
Volume
600
Avg. Volume
0
Mkt Cap
2,295
P/E Ratio
0
Dividend Yield
-
Dividend
-
Earnings
30SepConfirmed
Expected EPS
N/A
Actual EPS
-0.0043
People Also Follow
This list is based on the watchlists of people on Stock Events who follow RGMP. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Consumer Services
Software and Other Prerecorded Compact Disc, Tape, and Record Reproducing
Movies/Entertainment
Manufacturing
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
Show more...
CEO
Employees
1
Country
US
ISIN
US75915R1068